|
|
Cabling Services
|
AUG1700038421
|
$16,211
|
$16,211
|
N/A
|
N/A
|
|
|
ACM17001-001-00000
|
ACM17001
|
$38,000
|
$38,000
|
UNKNOWN, UNKNOWN
|
|
|
|
ACO13015-001-01002
|
ACO13015
|
$11,862
|
$11,862
|
UNKNOWN, UNKNOWN
|
|
|
|
Noninvasive Contrast Enhanced Early Detection of Melanoma Liver Metastasis
|
2R42CA183376-02X1
|
$46,492
|
$46,492
|
Yang
|
"INLIGHTA BIOSCIENCES, LLC"
|
|
|
Novel Materials for Viral Purification
|
1R43CA217454-01A1
|
$224,166
|
$224,166
|
MESSMER, BRADLEY
|
ABREOS BIOSCIENCES, INC.
|
|
|
Development of Tumor Proliferation PET Tracer FLT using a Low Cost Single Dose Automatic Production and Quality Control Biomarker Generator System
|
5R44CA195831-03
|
$711,781
|
$711,781
|
Bruckbauer, Thomas
|
ABT MOLECULAR IMAGING, INC.
|
|
|
OPTION YEAR 1 - PILOT TESTING A HEALTHCARE DELIVERY RESEARCH FELLOWSHIP PROGRAM (TASK 4) AS STATED IN THE SOW
|
261201600638P
|
$38,294
|
$38,294
|
UNKNOWN, UNKNOWN
|
ACADEMYHEALTH
|
|
|
The Madrina Network Web Portal
|
5R44CA177037-03
|
$688,585
|
$688,585
|
MATIELLA, ANA
|
ACMA SOCIAL MARKETING
|
|
|
Therapeutic disruption of Connexin43-mediated microtubule regulation to target glioblastoma cancer stem cells
|
1R41CA217503-01
|
$224,999
|
$224,999
|
LAMOUILLE, SAMY
|
ACOMHAL RESEARCH, INC.
|
|
|
PHOTOACOUSTIC NEEDLE FOR IDENTIFYING TUMOR CONTENT AND MARGINS TO IMPROVE SAMPLING DURING CORE NEEDLE BIOPSY, CAN# 8478658, POP 9/19/2017 - 9/18/2019
|
261201700050C
|
$1,499,895
|
$1,499,895
|
UNKNOWN, UNKNOWN
|
ACTUATED MEDICAL, INC.:1186368
|
|
|
IeDEA West Africa Renewal 3
|
U01AI069919-12
|
$225,000
|
$225,000
|
Dabis, Francois
|
ADERA
|
|
|
Modulation of Immune Checkpoints by Self-Deliverable RNAi for Adoptive Cell Transfer
|
1R43CA213632-01
|
$231,500
|
$231,500
|
WOLFSON, ALEXEY
|
ADVANCED RNA TECHNOLOGIES, LLC
|
|
|
Device Strategy for Selective Isolation of Oncosomes and Non-Malignant Exosomes
|
261201700022C*1
|
$299,250
|
$299,250
|
N/A
|
AETHLON MEDICAL, INC.
|
|
|
Peptide-based tool for the rapid isolation of quiescent monocytes from peripheral blood
|
1R43CA211061-01A1
|
$308,839
|
$308,839
|
DARBY, MARTYN
|
AFFINERGY, LLC
|
|
|
Integrin Regulation of Cancer Progression Through Alternative mRNA Splicing and Nonsense-Medidated Decay (NMD)
|
5R01CA129637-07
|
$375,250
|
$375,250
|
DIPERSIO, C. MICHAEL
|
ALBANY MEDICAL COLLEGE
|
|
|
Women's Interagency HIV Study (WIHS-V)
|
U01AI035004-25
|
$144,370
|
$144,370
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, IN
|
|
|
Central Africa International Epidemiologic Database to Evaluate AIDS
|
U01AI096299-08
|
$260,000
|
$260,000
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, IN
|
|
|
20/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 Research Projec
|
U01DK048349-25
|
$68,181
|
$68,181
|
CRANDALL, JILL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, IN
|
|
|
Einstein-Rockefeller-CUNY Center for AIDS Research
|
P30AI124414-01A1
|
$174,258
|
$174,258
|
GOLDSTEIN, HARRIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, IN
|
|
|
HIV/HPV Cancer Prevention, Treatment & Pathogenesis: Rwanda/Einstein Consortium
|
5U54CA190163-04
|
$701,778
|
$701,778
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
The sequence recognition, structure and function of the IMP family of mRNA binding proteins
|
1F30CA214009-01A1
|
$49,044
|
$49,044
|
BISWAS, JEETAYU
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Persistent HPV Infection in Women at Risk for Cervix Cancer
|
5U01CA078527-20
|
$581,591
|
$581,591
|
BURK, ROBERT
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Building Research Capacity to Address the Challenge of Non Communicable Diseases and Injuries in Rwanda The GUKORANA Research Center
|
1P20CA210284-01A1
|
$340,631
|
$340,631
|
CASTLE, PHILIP
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
(7) Novel imaging devices for measurement and control of tumor microenvironments
|
1R01CA216248-01
|
$565,675
|
$565,675
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Signal transduction regulating tumor cell dissemination
|
5R01CA150344-29
|
$396,625
|
$396,625
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer
|
5R01CA128943-09
|
$396,625
|
$396,625
|
DI CRISTOFANO, ANTONIO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
PI3K-mediated metabolic alterations in the pre-neoplastic thyroid
|
5R01CA167839-06
|
$346,525
|
$346,525
|
DI CRISTOFANO, ANTONIO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Designing Novel Anti-Cancer Therapeutics: Targeting Methionine Metabolism
|
1F30CA210372-01A1
|
$49,044
|
$49,044
|
FIRESTONE, ROSS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
The role of macroH2A variants in cancer and senescence
|
2R01CA155232-07
|
$382,013
|
$382,013
|
GAMBLE, MATTHEW
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Small Molecule Activators of Pro-apoptotic BAX for Cancer Therapy
|
5R01CA178394-04
|
$346,525
|
$346,525
|
GAVATHIOTIS, EVRIPIDIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Proton-coupled folate/antifolate transport
|
5R01CA082621-20
|
$483,169
|
$483,169
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
PI3K Isoform Dependence in Adult Hematopoiesis and Myeloid Leukemia
|
5R01CA196973-02
|
$409,153
|
$409,153
|
GRITSMAN, KIRA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Epigenetic activity of normal and cancer-associated mutant H1 linker histones
|
5F30CA210539-02
|
$44,044
|
$44,044
|
HEALTON, SEAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Roles of formins in breast cancer invasion
|
5R21CA205262-02
|
$217,935
|
$217,935
|
HODGSON, LOUIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Training of Surgeons for Studies of the Tumor Microenvironment
|
5T32CA200561-03
|
$277,522
|
$277,522
|
MICHLER, ROBERT
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Paul Calabresi Career Development Award for Clinical Oncology (K12)
|
5K12CA132783-09
|
$810,000
|
$810,000
|
PEREZ-SOLER, ROMAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
The Metastatic Cascade: Macrophages Lead the Way
|
5R01CA172451-06
|
$439,400
|
$439,400
|
POLLARD, JEFFREY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Methylthioadenosine Phosphorylase and AdoMet Synthetase in Cancer
|
5R01CA135405-10
|
$290,592
|
$290,592
|
SCHRAMM, VERN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Optimization of Non-Ablative Focused Ultrasound Therapy for Tumor Immunity
|
5F30CA200411-04
|
$49,044
|
$49,044
|
SKALINA, KARIN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Methylome characterization of bronchial epithelial projenitor cells
|
1R21CA209436-01A1
|
$216,172
|
$216,172
|
SPIVACK, SIMON
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Mechanisms of Formation and Progression of Preleukemic Stem Cells
|
1R01CA217092-01
|
$397,371
|
$397,371
|
STEIDL, ULRICH
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Role of a Novel Homeobox Transcription Factor (HLX) in Acute Myeloid Leukemia
|
5R01CA166429-06
|
$384,342
|
$384,342
|
STEIDL, ULRICH
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
OPTION PERIOD 2- PATIENT ACCRUAL AND TREATMENT 12/30/2016-12/29/2017
|
261201500022C
|
$453,713
|
$453,713
|
UNKNOWN, UNKNOWN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Contributions of sympathetic signals to prostate cancer progression.
|
5F30CA203446-02
|
$49,044
|
$49,044
|
ZAHALKA, ALI
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Dissecting Skp2 functions in pRb and p53 doubly deficient tumorigenesis
|
5R01CA201458-02
|
$382,013
|
$382,013
|
ZHU, LIANG
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Manufacture of Bulk Chemicals and Bulk Pharmaceutical Ingredients for Preclinical and Clinical Studies
|
261201700020C
|
$125,000
|
$125,000
|
DENYSENKO, SERGIY
|
ALCHEM LABORATORIES CORPORATION
|
|
|
SYNTHESIS OF NON-GMP SMALL MOLECULES FOR DRUG DISCOVERY. HHSN261201200012C; DTP-17-003; ALCHEM LABORATORIES, INC.; DSCB; PROJECT MC1-1; TO#19; WA NX232-107-165-004; CAN# 8487300; NEXT
|
261201200012C
|
$412,782
|
$412,782
|
UNKNOWN, UNKNOWN
|
ALCHEM LABORATORIES CORPORATION
|
|
|
NEXT TRIAPINE NX007-110-186-001 - PREPARE 500 GM OF TRIAPINE, DTP17-004, HHSN261201200020C
|
261201200020C
|
$381,725
|
$381,725
|
UNKNOWN, UNKNOWN
|
ALCHEM LABORATORIES CORPORATION
|
|
|
OPTION PERIOD ONE
|
261201600066C
|
$535,826
|
$535,826
|
UNKNOWN, UNKNOWN
|
ALCHEM LABORATORIES CORPORATION
|
|
|
SYNTHESIS OF NON-GMP MOLECULES; TO 1 CLIN2 $912.54 (REMAINING MIN. GUARANTEE AMT); HHSN261201700007I ALCHEM LABS; DTP-17-049; CAN 8487300 NEXT; FUNDING PERIOD 9/11/17-9/10/18
|
261201700007I
|
$1,000
|
$1,000
|
UNKNOWN, UNKNOWN
|
ALCHEM LABORATORIES CORPORATION
|
|
Total relevant funding to Cancer for this search: $3,357,352,468
|
